No black box warning on record for Cobenfy

As of the latest FDA labeling reviewed, Cobenfy (XANOMELINE AND TROSPIUM CHLORIDE) does not carry a black box warning. Standard warnings and precautions still apply — see the full Cobenfy medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS • Risk of Urinary Retention: COBENFY can cause urinary retention. Geriatric patients and patients with bladder outlet obstruction and incomplete bladder emptying are at increased risk. Monitor patients for symptoms of acute urinary retention. ( 5.1 ) • Risk of Use in Patients with Hepatic Impairment: COBENFY is contraindicated in patients with moderate to severe hepatic

No black box warning on record for Cobenfy

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS • Risk of Urinary Retention: COBENFY can cause urinary retention. Geriatric patients and patients with bladder outlet obstruction and incomplete bladder emptying are at increased risk. Monitor patients for symptoms of acute urinary retention. ( 5.1 ) • Risk of Use in Patients with Hepatic Impairment: COBENFY is contraindicated in patients with moderate to severe hepatic

Cobenfy Black Box Warning

No black box warning on record for Cobenfy

Other warnings & precautions

Cobenfy Black Box Warning

No black box warning on record for Cobenfy

Other warnings & precautions